Ceremorphic develops sustainable compute infrastructure using proprietary quantum-inspired qubit-based processing for high-performance AI supercomputing. This ground-up architecture addresses the performance and energy demands of modern LLM workloads. The technology also enables breakthrough architectures for in silico drug design in the life sciences sector.
Funding
$87M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The increasing complexity and size of AI models demand significant computational power, leading to high compute costs and energy consumption, which can hinder the development and deployment of AI applications, particularly in fields like drug discovery. Traditional drug discovery processes also suffer from inefficiencies, resulting in increased costs and longer development times.
Solution
Ceremorphic offers a novel AI supercomputing architecture designed to address the escalating demands of AI model training and in silico drug design. Their solution leverages a 3nm process technology and a proprietary multi-threaded processing architecture (ThreadArch®) to deliver energy-efficient, high-performance computing. This approach aims to reduce both compute costs and energy consumption while accelerating model training and enabling more efficient and cost-effective personalized medicine. The architecture is designed to support a wide range of markets and applications, including data centers, AI training, life sciences, automotive, robotics, and metaverse processing.
Target Audience
The primary target audience includes organizations involved in AI model training, drug discovery, and high-performance computing across various sectors such as data centers, life sciences, automotive, robotics, and metaverse processing.
Features
- Proprietary ThreadArch® multi-threaded processing architecture for enhanced performance
- Designed on a cutting-edge 3nm process technology
- Energy-efficient design to minimize power consumption
- Quantum-resistant security features
- Datacenter-in-a-Box™ solution for easy deployment
- BioCompDiscoverX™ platform for analog and AI-driven in silico drug design
- Over 200 patents